PubRank

Grace A McComsey

Author PubWeight™ 92.34‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med 2014 3.48
2 Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009 2.75
3 Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis 2011 2.35
4 Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2009 2.24
5 Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. J Infect Dis 2014 1.86
6 Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care 2010 1.86
7 Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther 2010 1.83
8 Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection. AIDS 2014 1.46
9 Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy. Clin Infect Dis 2013 1.36
10 Metabolic complications of HIV therapy in children. AIDS 2004 1.28
11 Vitamin D is linked to carotid intima-media thickness and immune reconstitution in HIV-positive individuals. Antivir Ther 2011 1.28
12 Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy and lipoatrophy. J Acquir Immune Defic Syndr 2008 1.25
13 Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy. J Acquir Immune Defic Syndr 2015 1.25
14 Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens. Antivir Ther 2011 1.23
15 Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation. Clin Infect Dis 2013 1.23
16 Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection. AIDS 2013 1.23
17 Fractures after antiretroviral initiation. AIDS 2012 1.21
18 Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: a randomized placebo-controlled trial. Antivir Ther 2011 1.14
19 HIV-1 is not a major driver of increased plasma IL-6 levels in chronic HIV-1 disease. J Acquir Immune Defic Syndr 2012 1.12
20 Metabolic complications and treatment of perinatally HIV-infected children and adolescents. J Int AIDS Soc 2013 1.09
21 Heightened inflammation is linked to carotid intima-media thickness and endothelial activation in HIV-infected children. Atherosclerosis 2010 1.08
22 Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 2013 1.05
23 Oxidized LDL Levels Are Increased in HIV Infection and May Drive Monocyte Activation. J Acquir Immune Defic Syndr 2015 1.05
24 A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness. AIDS 2015 1.05
25 Overall benefit of antiretroviral treatment on the risk of fracture in HIV: nested case-control analysis in a health-insured population. AIDS 2012 1.03
26 Risk factors for vitamin D deficiency and relationship with cardiac biomarkers, inflammation and immune restoration in HIV-infected youth. Antivir Ther 2012 1.03
27 Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals. J Acquir Immune Defic Syndr 2012 1.03
28 Longitudinal changes in carotid intima-media thickness and cardiovascular risk factors in human immunodeficiency virus-infected children and young adults compared with healthy controls. Pediatr Infect Dis J 2010 0.99
29 Relationships between inflammation, immune activation, and bone health among HIV-infected adults on stable antiretroviral therapy. J Acquir Immune Defic Syndr 2014 0.99
30 Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen. J Antimicrob Chemother 2009 0.99
31 Metabolic complications of antiretroviral therapy in children. Pediatr Infect Dis J 2003 0.96
32 Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial. Ann Intern Med 2015 0.95
33 A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy. AIDS Patient Care STDS 2012 0.94
34 Elevated D-dimer is independently associated with endothelial dysfunction: a cross-sectional study in HIV-infected adults on antiretroviral therapy. Antivir Ther 2012 0.94
35 Chemokine (C-C motif) receptor 5 -2459 genotype in patients receiving highly active antiretroviral therapy: race-specific influence on virologic success. J Infect Dis 2011 0.93
36 European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142. AIDS 2011 0.93
37 Changes in oxidized lipids drive the improvement in monocyte activation and vascular disease after statin therapy in HIV. AIDS 2016 0.92
38 Perivascular fat, inflammation, and cardiovascular risk in HIV-infected patients on antiretroviral therapy. Int J Cardiol 2013 0.92
39 C-reactive protein predicts 96-week carotid intima media thickness progression in HIV-infected adults naive to antiretroviral therapy. J Acquir Immune Defic Syndr 2014 0.91
40 Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study. Antivir Ther 2013 0.91
41 Rosuvastatin slows progression of subclinical atherosclerosis in patients with treated HIV infection. AIDS 2016 0.90
42 Omega-3 fatty acids do not improve endothelial function in virologically suppressed HIV-infected men: a randomized placebo-controlled trial. AIDS Res Hum Retroviruses 2011 0.89
43 Osteopenia and osteoporosis in patients with HIV: a review of current concepts. Curr Infect Dis Rep 2006 0.88
44 Lack of recurrence of hyperlactatemia in HIV-infected patients switched from stavudine to abacavir or zidovudine. J Acquir Immune Defic Syndr 2004 0.88
45 Statins to improve cardiovascular outcomes in treated HIV infection. Curr Opin Infect Dis 2016 0.87
46 Is bone loss linked to chronic inflammation in antiretroviral-naive HIV-infected adults? A 48-week matched cohort study. AIDS 2014 0.87
47 Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens. AIDS 2010 0.87
48 Impact of randomized antiretroviral therapy initiation on glucose metabolism. AIDS 2014 0.86
49 Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density. AIDS 2013 0.85
50 Statins Blunt HAART-Induced CD4 T-Cell Gains but Have No Long-Term Effect on Virologic Response to HAART. J Int Assoc Physicians AIDS Care (Chic) 2007 0.84
51 Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine. J Acquir Immune Defic Syndr 2014 0.84
52 Salsalate is poorly tolerated and fails to improve endothelial function in virologically suppressed HIV-infected adults. AIDS 2010 0.83
53 Inflammation Perturbs the IL-7 Axis, Promoting Senescence and Exhaustion that Broadly Characterize Immune Failure in Treated HIV Infection. J Acquir Immune Defic Syndr 2016 0.82
54 Changes in metabolic syndrome status after initiation of antiretroviral therapy. J Acquir Immune Defic Syndr 2015 0.82
55 Oxidant stress and peripheral neuropathy during antiretroviral therapy: an AIDS clinical trials group study. J Acquir Immune Defic Syndr 2006 0.82
56 Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival. Infect Dis Clin North Am 2005 0.82
57 Effects of randomized rosuvastatin compared with placebo on bone and body composition among HIV-infected adults. AIDS 2015 0.81
58 Carotid intima media thickness, inflammatory markers, and endothelial activation markers in HIV Patients with lipoatrophy increased at 48 weeks regardless of use of rosiglitazone or placebo. AIDS Res Hum Retroviruses 2010 0.81
59 Short communication: initiation of an abacavir-containing regimen in HIV-infected adults is associated with a smaller decrease in inflammation and endothelial activation markers compared to non-abacavir-containing regimens. AIDS Res Hum Retroviruses 2012 0.81
60 First reported case of Neisseria meningitidis periorbital cellulitis associated with meningitis. Pediatrics 2005 0.81
61 Long-term body composition changes in antiretroviral-treated HIV-infected individuals. AIDS 2016 0.80
62 Vitamin D deficiency and altered bone mineral metabolism in HIV-infected individuals. Curr HIV/AIDS Rep 2014 0.79
63 Cardiovascular disease risk in pediatric HIV: the need for population-specific guidelines. J Acquir Immune Defic Syndr 2011 0.79
64 Rate and predictors of carotid artery intima media thickness progression in antiretroviral-naive HIV-infected and uninfected adults: a 48-week matched prospective cohort study. Antivir Ther 2013 0.79
65 Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation: ACTG A5224s. J Acquir Immune Defic Syndr 2015 0.79
66 Habitual nutrient intake in HIV-infected youth and associations with HIV-related factors. AIDS Res Hum Retroviruses 2014 0.78
67 Vitamin D and bone loss in HIV. Curr Opin HIV AIDS 2016 0.78
68 Statin therapy and changes in hip circumference among HIV-infected participants in the ALLRT Cohort. Antivir Ther 2009 0.78
69 New entrants to HIV care are presenting only at marginally earlier stages of disease but may increasingly represent groups perceived at lower risk. J Int Assoc Physicians AIDS Care (Chic) 2005 0.78
70 Subjective clinical lipoatrophy assessment correlates with DEXA-measured limb fat. HIV Clin Trials 2009 0.78
71 Long-term changes in carotid intima-media thickness among HIV-infected children and young adults. Antivir Ther 2013 0.78
72 Elevated Red Cell Distribution Width (RDW) Identifies Elevated Cardiovascular Disease Risk in Patients with HIV infection. J Acquir Immune Defic Syndr 2016 0.78
73 Bone loss in HIV: a contemporary review. Curr Opin Endocrinol Diabetes Obes 2015 0.77
74 Higher plasma myeloperoxidase levels are not associated with an increased risk for cardiovascular events in HIV-infected adults. HIV Clin Trials 2008 0.77
75 The relationship between vitamin D status and HIV-related complications in HIV-infected children and young adults. Pediatr Infect Dis J 2013 0.77
76 Cord blood lipids in infants born to HIV-1-infected women treated with combination antiretroviral therapy. Antivir Ther 2008 0.77
77 Lipids and lactate in human immunodeficiency virus-1 infected pregnancies with or without protease inhibitor-based therapy. Obstet Gynecol 2007 0.77
78 The effect of physical activity on cardiometabolic health and inflammation in treated HIV infection. Antivir Ther 2015 0.76
79 LL-37 concentrations and the relationship to vitamin D, immune status, and inflammation in HIV-infected children and young adults. AIDS Res Hum Retroviruses 2014 0.76
80 Statin therapy decreases N-terminal pro-B-type natriuretic peptide in HIV: randomized placebo-controlled trial. AIDS 2015 0.76
81 HIV vasculopathy: role of mononuclear cell-associated Krüppel-like factors 2 and 4. AIDS 2015 0.76
82 Short communication: High prevalence of vitamin D deficiency in HIV-infected and HIV-uninfected pregnant women. AIDS Res Hum Retroviruses 2013 0.76
83 Changes in Inflammation, Oxidative Stress, Mitochondrial DNA Content after Rosiglitazone in HIV Lipoatrophy. J AIDS Clin Res 2012 0.76
84 Effects of HIV and antiretroviral therapy on resting energy expenditure in adult HIV-infected women-a matched, prospective, cross-sectional study. J Acad Nutr Diet 2013 0.76
85 Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1 infection. AIDS 2016 0.76
86 Adipokines and vascular health in treated HIV infection: an obesity paradox? AIDS 2013 0.76
87 Comprehensive assessment of the arginine pathway and its relationship to inflammation in HIV. AIDS 2016 0.75
88 Dendritic cell recruitment in response to skin antigen tests in HIV-1-infected individuals correlates with the level of T-cell infiltration. AIDS 2013 0.75
89 Bone effects of rosiglitazone in HIV-infected patients with lipoatrophy. HIV Clin Trials 2012 0.75
90 Increased Immune Activation and Exhaustion in HIV-infected Youth. Pediatr Infect Dis J 2016 0.75
91 The role of statins in the setting of HIV infection. Curr HIV/AIDS Rep 2015 0.75
92 Fatty liver in HIV infection: metabolic syndrome, medicines, mitochondria, and more? AIDS Read 2007 0.75
93 Anaemia is associated with monocyte activation in HIV-infected adults on antiretroviral therapy. Antivir Ther 2015 0.75
94 Baseline vitamin D deficiency decreases the effectiveness of statins in HIV-infected adults on antiretroviral therapy. J Acquir Immune Defic Syndr 2016 0.75
95 Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults. HIV Clin Trials 2015 0.75
96 Insulin Resistance and Markers of Inflammation in HIV-Infected Ugandan Children in the CHAPAS 3 Trial. Pediatr Infect Dis J 2017 0.75
97 Antiretroviral initiation is associated with increased skeletal muscle area and fat content. AIDS 2017 0.75
98 Racial differences in calculated bioavailable vitamin D with vitamin D/calcium supplementation: ACTG A5280. AIDS 2017 0.75
99 Effects of Vitamin D Supplementation on Bone Mineral Density and Bone Markers in HIV-infected Youth. J Acquir Immune Defic Syndr 2017 0.75
100 HIV positive youth who are perinatally infected have impaired endothelial function. AIDS 2017 0.75
101 Buffalo hump: what the experts suggest. AIDS Clin Care 2004 0.75
102 Index of suspicion. Pediatr Rev 2006 0.75